L14-8

L14-8 is a potent ferroptosis inducer. L14-8 promotes PLK1 degradation via ubiquitination, increasing TP53 phosphorylation to enhance SAT1 transcription, thereby triggering ferroptosis and cancer cell death. L14-8 can be used for the study of advanced prostate cancer[1].

Product Specifications

UNSPSC

12352005

Target

Ferroptosis; MDM-2/p53; Polo-like Kinase (PLK)

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Endocrinology

Smiles

FC1=CC=C([C@@H](OC(C=C)=O)CC[C@@H]2[C@@H](C3=CC=C(OC(C=C)=O)C=C3)N(C4=CC=C(F)C=C4)C2=O)C=C1

Molecular Formula

C30H25F2NO5

Molecular Weight

517.52

References & Citations

[1]Zhang Y, et al. Ezetimibe Engineered L14-8 Suppresses Advanced Prostate Cancer by Activating PLK1/TP53-SAT1-Induced Ferroptosis. Adv Sci (Weinh) . 2025 Jun 19:e04192.